Figini M, Ricciardolo F L, Javdan P, Nijkamp F P, Emanueli C, Pradelles P, Folkerts G, Geppetti P
Institute of Internal Medicine IV, University of Florence, Italy.
Am J Respir Crit Care Med. 1996 Mar;153(3):918-23. doi: 10.1164/ajrccm.153.3.8630573.
Bradykinin, applied locally to the airways, is a weak bronchoconstrictor agent in guinea pigs in vivo and it may cause constriction or dilatation of guinea pig airways smooth muscle in vitro. We examined the motor effect of bradykinin perfused through the lumen of isolated guinea pig tracheal tubes with or without nitric oxide (NO) synthase inhibitors. In the presence of NG-nitro-D-arginine methyl ester (D-NAME) or NG-monomethyl-D-arginine (D-NMMA) intraluminal bradykinin caused a moderate concentration-dependent relaxation. In contrast, in the presence of NG-nitro-L-arginine methyl ester (L-NAME) or NG-monomethyl-L-arginine (L-NMMA) tracheas developed a sustained increase in tone, and bradykinin caused a marked, concentration-dependent contraction, both effects being reversible by pretreatment with L-arginine, but not with D-arginine. The ability of bradykinin to relax (in the presence of D-NAME) or contract (in the presence of L-NAME) guinea pig tracheal tubes was not affected by indomethacin. Bradykinin contracted epithelium-denuded tracheas in the presence of either L-NAME or D-NAME. Both contraction and relaxation by bradykinin were blocked by the kinin B2 receptor antagonist, HOE 140. Baseline production of guanosine 3',5'-cyclic monophosphate (cyclic GMP) in strips of guinea pig trachealis in vitro was markedly reduced by L-NAME, but not by D-NAME. Bradykinin increased baseline cyclic GMP concentration. These results indicate that bradykinin releases NO or a NO-related molecule, which, possibly by increasing cyclic GMP concentrations, mediates relaxation and opposes contraction induced by bradykinin itself, and further, that bradykinin releases NO from the tracheal epithelium.
缓激肽局部应用于气道时,在豚鼠体内是一种较弱的支气管收缩剂,而在体外它可能会引起豚鼠气道平滑肌的收缩或舒张。我们研究了在有或没有一氧化氮(NO)合酶抑制剂的情况下,缓激肽灌注通过离体豚鼠气管管腔时的运动效应。在存在NG-硝基-D-精氨酸甲酯(D-NAME)或NG-单甲基-D-精氨酸(D-NMMA)的情况下,管腔内缓激肽引起适度的浓度依赖性舒张。相反,在存在NG-硝基-L-精氨酸甲酯(L-NAME)或NG-单甲基-L-精氨酸(L-NMMA)的情况下,气管张力持续增加,缓激肽引起明显的浓度依赖性收缩,这两种效应均可通过L-精氨酸预处理而逆转,但不能通过D-精氨酸逆转。缓激肽使豚鼠气管舒张(在D-NAME存在下)或收缩(在L-NAME存在下)的能力不受吲哚美辛影响。在L-NAME或D-NAME存在下,缓激肽使去上皮气管收缩。缓激肽引起的收缩和舒张均被缓激肽B2受体拮抗剂HOE 140阻断。L-NAME可显著降低体外豚鼠气管条中鸟苷3',5'-环磷酸(环鸟苷酸)的基础生成量,但D-NAME则无此作用。缓激肽可增加基础环鸟苷酸浓度。这些结果表明,缓激肽释放NO或一种与NO相关的分子,该分子可能通过增加环鸟苷酸浓度来介导舒张并对抗缓激肽自身诱导的收缩,此外,缓激肽可从气管上皮释放NO。